These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27085537)

  • 21. Interleukin-7 receptor expression in cutaneous T-cell lymphomas.
    Bagot M; Charue D; Boulland ML; Gaulard P; Revuz J; Schmitt C; Wechsler J
    Br J Dermatol; 1996 Oct; 135(4):572-5. PubMed ID: 8915148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy.
    Yu JB; McNiff JM; Lund MW; Wilson LD
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1542-5. PubMed ID: 18037577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD30-positive cutaneous extranodal natural killer/T-cell lymphoma: clinicopathological features and survival outcomes.
    Lee WJ; Moon IJ; Shin HJ; Won CH; Chang SE; Choi JH; Lee MW
    Int J Dermatol; 2019 Jun; 58(6):688-696. PubMed ID: 30597548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma.
    Beljaards RC; Meijer CJ; Van der Putte SC; Hollema H; Geerts ML; Bezemer PD; Willemze R
    J Pathol; 1994 Jan; 172(1):53-60. PubMed ID: 7931828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary cutaneous T-cell lymphoma occurring after organ transplantation.
    Ravat FE; Spittle MF; Russell-Jones R
    J Am Acad Dermatol; 2006 Apr; 54(4):668-75. PubMed ID: 16546591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
    J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins.
    Boulland ML; Wechsler J; Bagot M; Pulford K; Kanavaros P; Gaulard P
    Histopathology; 2000 Feb; 36(2):136-44. PubMed ID: 10672058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD30-Positive Lymphoproliferative Disorders.
    Nikolaenko L; Zain J; Rosen ST; Querfeld C
    Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
    Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R
    Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior.
    Vermeer MH; van Doorn R; Dukers D; Bekkenk MW; Meijer CJ; Willemze R
    J Clin Oncol; 2001 Dec; 19(23):4322-9. PubMed ID: 11731515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia: clinical characteristics, temporal relationships, and survival data in a series of 14 patients at Mayo Clinic.
    Chang MB; Weaver AL; Brewer JD
    Int J Dermatol; 2014 Aug; 53(8):966-70. PubMed ID: 24134412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma.
    Su IJ; Tsai TF; Cheng AL; Chen CC
    J Am Acad Dermatol; 1993 Nov; 29(5 Pt 1):685-92. PubMed ID: 8227539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas.
    van Haselen CW; Vermeer MH; Toonstra J; van der Putte SC; Mulder PG; van Vloten WA; Willemze R
    J Cutan Pathol; 1997 Sep; 24(8):462-7. PubMed ID: 9331891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary cutaneous CD30(+) lymphoproliferative disorders.
    Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
    J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
    Duvic M; Donato M; Dabaja B; Richmond H; Singh L; Wei W; Acholonu S; Khouri I; Champlin R; Hosing C
    J Clin Oncol; 2010 May; 28(14):2365-72. PubMed ID: 20351328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brentuximab vedotin in CD30
    Enos TH; Feigenbaum LS; Wickless HW
    Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.
    Kim YH; Chow S; Varghese A; Hoppe RT
    Arch Dermatol; 1999 Jan; 135(1):26-32. PubMed ID: 9923777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II.
    Paulli M; Berti E
    Haematologica; 2004 Nov; 89(11):1372-88. PubMed ID: 15531460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.